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A rapid LC-MS/MS method for quantification
of CSUOH0901, a novel antitumor agent, in rat
plasma
Ramakrishna R. Voggu, Ravali Alagandula, Xiang Zhou, Bin Su,
Bo Zhong and Baochuan Guo

Introduction
CSUOH0901 {benzo [1,3] dioxole-S-carboxylicacid [3-(2,5-dimethylbenzyloxy)-4-(methanesulfonylmethylamino)-phenyl] amide}
(NSC751382; Fig. 1C; Zhong et al., 2013) is a novel, secondgeneration anticancer agent derived from nimesulide, which
can inhibit cyclooxygenase-2 (COX-2; Fig. 1A). In cancer therapy,
nimesulide showed hepatotoxicity on long-term usage and required higher concentrations to inhibit COX-2 activity (Zhong
et al., 2012). This led to the development of CSUOH0901, a
nimesulide derivative, which exhibited very promising anticancer
activities by interacting with tubulin and Hsp27 proteins, which
are important to cancer cell proliferation. CSUOH0901 inhibited
the proliferation of cancer cells of lung, breast, colon, CNS, ovary,
renal and prostate cancer with an IC 50 of 0.1-0.5 µM, which is 10fold more active than JCC76 {N-[3-(2,5-dimethylbenzyloxy)-4(methylmethylsulfonamido) phenyl] cyclohexanecaboxamide;
(Fig. 1B; Suleyman et al., 2008) and 1000-fold more potent than
nimesulide (Zhong et al., 2013).
Recent docking studies in SKBR-3 breast cancer cell lines
(Suleyman et al., 2008; Yi et al., 2012) revealed that CSUOH0901
interacted with both a- and /J-tubulin in the colchicine pocket
and disorganized microtubules. Additionally, interaction of heat
shock protein 27 (Hsp27) (Sun and MacRae, 2005) with
CSUOH0901 inhibited the phosphorylation of Hsp27, leading to
cell apoptosis. Hsp27 is a stress protein that is expressed when
cells are stimulated by heat (Kampinga et al., 1995; Stege et al.,
1995a, 1995b), radiation (Rau et al., 1999), chemotherapeutic
drugs (Ciocca et al., 1992) or other agents (Wu and Welsh,
1996). A recent study showed that cancer cells with HSP27 overexpression were resistant to chemotherapeutic drugs (Huot

et al., 1991; Fuqua et al., 1994; Hettinga et al., 1996; Richards
et al., 1996). Antisense to inhibition of the HSP27 gene decreased cellular resistance to chemotherapy as well as to heat
shock (Horman et al., 1999). Other studies have suggested that
HSP27 prevents cancer cells from apoptosis and dramatically enhances their tumorigenicity (Garrido et al., 1998, 1999; Guenal
et al., 1997; Samali and Cotter, 1996). Mass spectrometric studies
revealed that tubulin and Hsp27 proteins are the most prevalent
targets of CSUOH0901. Recent in vivo studies demonstrated that
CSUOH0901 significantly decreased the size of HT29 tumors in a
xenograft model compared with the control group, suggesting
the low toxicity and high potency in vivo (Zhong et al., 2012).
Clearly, CSUOH0901 is a very promising anticancer drug candidate and will be further studied. However, to date, no LCMS/MS method has been developed for the quantification of
CSUOH0901. Therefore, a simple and accurate method to quantify CSUOH0901 is needed that will be essential to the future
pharmacological and toxicological studies of CSUOH0901. In this
work, a rapid and sensitive LC-MS/MS method was developed
and validated for quantitative determination of CSUOH0901 in
rat plasma. We demonstrated that the method developed was
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Plasma samples were removed from the 20 ° C freezer and thawed to
room temperature. Single and double blanks were prepared by spiking
10 µL o f acetonitrile in 200 µL o f rat plasma. Then 10 µL of IS working
solution was spiked in all calibration, QC solutions and single blank. ex
cept in double blank and vortexed immediately for 30 s. The samples
were deproteinized by adding 800 µL o f acetonitrile and sonicated for
15 min followed by centrifugation at 13,000g for 15 min. The superna
tants were transferred into autosampler vials for LC MS/MS analysis.

LC-MS/MS analysis
LC MS/MS analysis was conducted using 5500 QTRAP triple quadrupole,
tandem mass spectrometer (AB Sciex, Toronto, Canada) with an
electrospray ionization (ESO source (Framingham, MA, USA) interfaced with
high performance liquid chromatography (HPLC, Shimadzu, Columbia, MD,
USA) with two LC 30 AD pumps, DUG 20A3R inline degasser, a SIL 30 AC
autosampler, a CBM 20A controller and a CTO 10AVP column oven
(Shimdazu, Tokyo, Japan). Analyst software, version 1.52 (AB Sdex) was
used to control all the parameters o f tandem mass spectrometer and HPLC.

CSUOH0901
Figure 1. The chemical structures o f nimesulide (A), internal standard
.JCC76 (B) and CSUOH0901 (Q.

fast, sensitive and specific for quantifying CSU0H0901 in plasma,
and can be used in pharmacological studies.

Experimental
Chemical and reagents
CSUOH0901 and .JCC76 (internal standard, IS) were synthesized and pu
rified according to the previously published procedures (Zhong et al.,
2013; Suleyman et al., 2008). HPLC grade methanol and acetonitrile were
purchased from Pharmco Apper (Philadelphia, PA, USA). Formic acid,
ammonium formate and ammonium acetate were purchased from
Sigma Aldrich Chemical Company (Allentown, PA, USA). Dimethyl sulfox
ide was obtained from Fisher Scientific (Pittsburgh, PA, USA). Deionized
water was generated from a Barnstead Nano Pure Water Purification Sys
tern from Thermo Scientific (Waltham, MA, USA). Sprague Dawley rat
plasma K2 with specific lot numbers (10577 01 06) was purchased from
Innovative research (Novi, Ml, USA).

Calibration standard and quality control samples
Preparation o f stock and working solutions.
The stock solutions o f
CSUOH0901 and .JCC76 (IS) were prepared in dimethyl sulfoxide (DMSO)
at 1 m g / m l and stored at 20°C. A set o f CSOH0901 working solutions o f
10, 20, 50, 150, 400, 1000 and 2000 n g / m l were prepared by serial dilu
tion from the stock solution with DMSO. The working solution o f JCC76
(IS) was obtained by diluting the stock solution with DMSO to give a con
centration o f 150 ng/ml.
Preparation o f calibration and quality control plasma sam pies.
The
calibration plasma solutions were prepared by spiking 10 µL o f
CSUOH0901 working solutions in 200 µL o f blank plasma (mixture of 6
lots) to give drug concentrations of 0.5, 1.0, 2.5, 7.5, 20, 50 and 100
ng/mL The lower limit of quantification (LLOQ) and quality control (QC)
standards were prepared in a similar way at 0.5, 1.25, 10, 80 ng/ml,
representing LLOQ, low QC (LQC), middle QC (MQC) and high QC (HQ()
respectively. The QC and calibration samples were frozen at 20 ° C over
night. and then treated by the following sample preparation procedure
and subjected t o LC MS/MS analysis.

A Luna C18 (2) HPLC column (50 x2.0 m m 5 µm) with a C18 security
guard cartridge from Phenomenex (Torrance, CA, USA) was used for
the chromatographic separation o f the supernatants from the
deproteinized samples. An optimized gradient flow o f mobile phase A,
5 mM ammonium formate in 2% methanol, and mobile phase B, 5mM
ammonium formate in 90% methanol at a flow rate of 0 2 mUmin, was
developed. The column was equilibrated with the mobile phase for 10
min and the run time was 8 min for each run with 10 µL injection vol
ume. The positive ESI mode was selected and the MRM (multiple reac
tion monitoring) function was used for quantification, with the
transitions set at m/z 483.2 -+404.3, rn/z 4832 -+119.0 for CSUOH0901
and m/z 445.3 -+366 .3 for JCC76 (IS) (Fig. 2). The dwell time for each
MRM transition was set at 120 ms. Source dependent parameters were
optimized by flow infusion analysis: nebulization gas (30), heating gas
(30), curtain gas (40), ion spray voltage (5000 eV) and temperature
(450°C). Compound dependent parameters were manually optimized
as following: declustering potential, 180; entrance potential, 1O; collision
energy, 20; and cell exit potential, 12.

Analytical method validation
A full method validation was performed using rat plasma according to
the currently accepted FDA bioanalytical method guidelines (US Food
and Drug Administration, 2001) and also other references (Liu et al.
2013; Ito et al., 2013). The entire method was validated for precision, ac
curacy, linearity, selectivity, extraction recovery, LLOQ, matrix effect and
stability studies.
Calibration curve, linearity and sensitivity.
Seven CSUOH0901
plasma calibrators at the concentrations of 0.5, 1.0, 2.5, 7.5, 20, 50 and
100 ng/ml, double blank and single blank (only JCC76 internal standard)
were selected to establish a calibration curve. The weighed linear reg res
sion, 1/x, as weighing factor was used to calculate the slope and correla
tion coefficient o f the calibration curve. The LLOQ was defined as the
concentration with precision (coefficient o f variation, CV) <20%.
Accuracy and precision.

Intra and inter assay precision and accuracy

studies were performed using three QC standards, LQC, MQC and HQC,
at 1.25, 10 and 80 n g / m l with five replicates (n =5). Intra and inter assay
precisions were determined as CV, and accuracies were cakulated by
comparing experimentally determined concentrations with the spiked
values. Therefore, accuracy (%) = [(experimental concentration
spiked
concentration)/ spiked concentration) x 100.
Recovery and matrix effect.
The absolute extraction recovery was
determined by comparing the peak areas o f CSUOH0901 in QC samples
at 1.25, 10 and 80 n g / m l (CSUOH0901 added prior to deproteinization)
with those of postextraction samples (CSUOH0901 added after

799

(A)
366.3
100%
119.1

�

ii

50%
'Ce

I

445.3

o

#'

N/

o=s=o

I

0%

120

160

200

240

280

m/z, Da

320

360

(B)
100%

ii

400

440

404.3
119.0

483.2

I
"'CC'
I
ff

50%

N/

O=S=O

I

0%

120

160

200

240

280

320

m/z, Da

360

400

440

480

Figure 2. Precursor/product ion spectra and proposed fragmentation pathways for internal standard JCC76 (A) and analyte CSUOH0901 (B).
deproteinization) of corresponding concentrations. The relative recovery
was determined by comparing peak area ratio of CSUOH0901 and IS
(JCC76) spiked in plasma before extraction with that in postextraction
spiked samples.
The absolute matrix effect was calculated by comparing the peak
areas of postextraction blank plasma samples spiked with CSUOH0901
(1.25, 10 and 80 ng/ml) with those of corresponding standard solutions
at equivalent concentrations. The relative matrix effect was calculated by
comparing the peak area ratio of CSUOH0901 and IS (JCC76) spiked in
the blank plasma postextraction solution with that in standard solution.

Stability studies
Effect of freeze thaw on CSUOH0901 in plasma. Two QC samples
of 1.25 and 80 ng/ml concentrations were selected to verify their stabil
ity. The stability test for CSUOH0901 in plasma was studied after three
freeze thaw cycles over a 3 day period.
Short- and long-term stability studies of analyte in plasma. The
stability studies of CSUOH0901 in rat plasma were performed using
two QC standards (1.25 and 80 ng/ml), which were kept under different
storage conditions: 10 h at room temperature and 6 months at 20 ° C,
before and after sample extraction.
Stability of analyte in stock solutions. The stability studies of stock
solutions and working solutions of CSUOH0901 and internal standard
(JCC76) were also evaluated. The stock solutions of analyte were stored
°
at 20 C for 7 months. Two QC standards of concentrations 1.25 and
80 ng/ml were prepared from both the stored and fresh stock solutions
and the experimentally determined concentrations of CSUOH0901 were
compared (n =3 for each sample).

Results and discussion
Optimization of mass spectrometric conditions for MRM
quantitation

Positive ionization mode was selected to detect and optimize the
MS parameters for the detection of both CSUOH0901 and JCC76
(internal standard). It was found that the standard CSUOH0901
and JCC76 solutions prepared in methanol-water (9:1, v/v)
yielded higher intensity when compared with the solutions prepared in acetonitrile-water (9:1, v/v). Fragmentation led to the
formation of daughter ions in the product ion scan mode (Fig. 2).
Based on the fragmentation study, the MRM transitions of m/z
483.2 --->404.3 for CSUOH0901 and 445.3 --->366.3 for JCC76 were
selected for quantification, as these product ions yielded strong
signals. The highest MS signal was obtained by fine-tuning collision energy, spray voltage and ion source temperature.
Optimization of HPLC conditions

To overcome the irreproducibility and matrix effect problems associated with the isocratic flow, a gradient flow of mobile phase
A, SmM ammonium formate in 2% methanol, and mobile phase
B, 5 mM ammonium formate in 90% methanol with 0.2 ml/min
flow rate, was employed. This gradient flow improved the sensitivity and signal-to-noise ratio with a total run time of 18 min.
High concentration of methanol was used to elute CSUOH0901
from ( 18 column, owing to its low solubility in water with
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Figure 3. (A) Multiple reaction monitoring chromatograms of blank rat plasma in both IS and analyte windows. (B) IS JCC76 (10 ng/ml, S.58 min) and
CSUOH0901 at LLOQ level (0.5 ng/ml, 5.10 min).

predicted logo value of 4.86. The intensity of CSUOH0901 was
increased 2-fold when 5 mM ammonium formate buffer was
used in the mobile phases and the retention times were around
5.09 min for CSUOH0901 and 5.58 min for JCC76 (IS) (Fig. 38).
Linearity, sensitivity, selectivity and LLOQ

the Calibration curve for CSUOH0901 in plasma was linear in the
range of 0.5-100 ng/ml. Linearity results showed the quadratic
fit for CSUOH0901 with a seven-point calibration curve of concentrations 0.5, 1.0, 2.5, 7.5, 20, 50 and 100 ng/ml including
double-blank and single-blank (only JCC76 internal standard)
plasma samples. An excellent linearity was obtained with the
correlation coefficient of 0.9996 and the linear regression equation was y =0.073x 0.0085. This method exhibited high selectivity with no interfering peak in six different blank plasma
samples from different sources. The LLOQ was found to be 0.5
ng/ml, where the signal intensity was 20-fold higher than the

blank signal (Fig. 3). The lowest concentration in a calibration
curve (LLOQ) was quantified with the accuracy and precision
within 15% (Table 1).
Table 1. Accuracy and precision of CSUOH0901 calibration

standards (n =5) over 0.5-100 ng/ml

Nominal
concentration
(ng/ml)

0.5
1
2.5
7.5
20
50
100

Determined
concentration

Accuracy

Precision

0.49±0.01
0.90±0.09
2.58±0.08
7.23 ±0.27
20.42±0.42
49.14±0.86
97.30 ± 2.70

2.0%
10.0%
3.2%
3.6%
2.1%
1.7%
2.7%

4.5%
6.0%
6.7%
11.0%
1.7%
1.6%
2.2%

(ng/ml)

(RE)

(CV)

801
Table 2. Inter- and intra-assay accuracy and precision of CSUOH0901 in rat plasma

Intra- assay
Spiked
(ng/ml)

Inter- assay

Determined
(ng/ml)

Accuracy
(%RE)

SD

Precision
(CV)

Determined
(ng/ml)

Accuracy
(RE)

SD

Precision
(CV)

1.39
10.26
78.52

11.2%
2.6%
1.9%

0.04
0.18
1.44

2.9%
1.8%
1.8%

1.39
10.35
79.58

11.2%
3.5%
0.5%

0.07
0.46
4.36

5.0%
4.5%
5.5%

1.25
10
80

Accuracy and precision

Intra- and inter -assay accuracies of the validated method ranged
from 1.9 to 11.2% and from 0.5 to 11.2%, respectively. The intraand inter-assay precision values ranged from 1.8 to 2.9% and
from 4.5 to 5.5%, respectively. The inter- and intra-assay accuracy
and precision of the QC samples are depicted in Table 2.
Extraction recovery and matrix effect

The absolute recoveries of the extraction method were 104.0,
105.0 and 104.0% for the QC standards at 1.25, 10, and 80
ng/ml, and the relative recoveries of the extracted method were
99.9, 96.1 and 97.7% for the QC standards at 1.25, 10, and 80
ng/ml, respectively, as indicated in Table 3. Absolute matrix effects for each of three plasma samples at 1.25, 10, and 80
ng/ml were 5.5, 8.1 and 9.9%, and relative matrix effects were
2.6, 5.1 and 12.4% indicating the minimal matrix effect. Hence,
the protein precipitation technique for sample preparation was
found to be effective, as it not only extracted the analyte and internal standard well but also removed impurities causing interferences from the sample matrix.
Performing MRM confirmed the absence of significant matrix
effect by comparing the peak areas ratio of CSUOH0901 MRM
transitions (MRM 1 , m/z 483.2 ---->404.3; and MRM 2 , m/z 483.2
----> 119.0) for the spiked rat plasma samples with the average
peak area ratio for seven calibrators:
MRM ratio = peak area MRM 1 /peak area MRM 2

(1)

The average MRM ratio of the seven calibrators was 1.5 ±1.9
(±SD). This confirmed the absence of matrix effect in the plasma
samples and that they are in the acceptable range.

CSUOH0901 was stable for at least 8 h at room temperature
(bench top) and for 10 h when postextracted at room temperature and the results were summarized in Table 4. The recovery of
Table 3. Absolute and relative matrix effect and recovery of

CSUOH0901 in rat plasma

1.25
10
80

Stability

Concentration
(ng/ml)

Recovery
(%)

Bench-top (8 h)
At room temperature

1.25
80.00

112.0%
99.1%

Freeze-thaw (three cycles)

1.25
80.00

112.0%
104.5%

Post-extraction (10 h) at room
temperature

1.25
80.00

106.4%
97.8%

Table 5. Stabilities of CSUOH0901 and JCC76 Stock solutions

after storage at

20 ° ( for 6 months

Type of solutions
CSUOH0901 stock solution
JCC76 stock solution
CSUOH0901 working solution
JCC76 working solution

Concentration Recovery (%)
1 mg/ml
1 mg/ml
25 ng/ml
1600 ng/ml
150 ng/ml

111.8%
106.0%
99.6%
105.0%
124.6%

CSUOH0901 was 112.0% at LQC and 104.5% at HQC levels after
three freeze-thaw cycles. Stability studies of stock solutions and
working solutions of CSUOH0901 and internal standard (JCC76)
were performed by storing them at 20 ° ( for at least 6 months.
The analyte and the internal standard were found to be stable in
stock solutions and the results are summarized in Table 5.

Conclusion

Stability

Concentration
of QC samples
(ng/ml)

Table 4. Stabilities of CSUOH0901 under various conditions

Matrix effect

Recovery

Absolute

Relative

Absolute

Relative

5.5%
8.1%
9.9%

2.6%
5.1%
12.4%

104.0%
105.0%
104.0%

99.9%
96.1%
97.7%

In conclusion, a highly sensitive LC-MS/MS method for the quantitation of CSUOH0901 in rat plasma was developed and validated for the first time. The method developed has a short run
time of 18 min employing a simple one-step sample preparation.
The accuracy and precision were <10% and the LLOQ was as
low as 0.5 ng/ml. The results from the validation studies illustrated that this method can be used to determine the pharmacological and toxicological profiles of CSUOH0901 in rats.
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